Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 342

1.

TRAIL, OPG, and TWEAK in kidney disease: biomarkers or therapeutic targets?

Bernardi S, Voltan R, Rimondi E, Melloni E, Milani D, Cervellati C, Gemmati D, Celeghini C, Secchiero P, Zauli G, Tisato V.

Clin Sci (Lond). 2019 May 16;133(10):1145-1166. doi: 10.1042/CS20181116. Print 2019 May 31. Review.

2.

Actively targeted nanocarriers for drug delivery to cancer cells.

Biffi S, Voltan R, Bortot B, Zauli G, Secchiero P.

Expert Opin Drug Deliv. 2019 May;16(5):481-496. doi: 10.1080/17425247.2019.1604679. Epub 2019 May 2.

PMID:
30955393
3.

Targeting mTOR in Acute Lymphoblastic Leukemia.

Simioni C, Martelli AM, Zauli G, Melloni E, Neri LM.

Cells. 2019 Feb 21;8(2). pii: E190. doi: 10.3390/cells8020190. Review.

4.

Role of physical exercise in the regulation of epigenetic mechanisms in inflammation, cancer, neurodegenerative diseases, and aging process.

Ferioli M, Zauli G, Maiorano P, Milani D, Mirandola P, Neri LM.

J Cell Physiol. 2019 Feb 14. doi: 10.1002/jcp.28304. [Epub ahead of print] Review.

PMID:
30767204
5.

HelixComplex snail mucus exhibits pro-survival, proliferative and pro-migration effects on mammalian fibroblasts.

Trapella C, Rizzo R, Gallo S, Alogna A, Bortolotti D, Casciano F, Zauli G, Secchiero P, Voltan R.

Sci Rep. 2018 Dec 5;8(1):17665. doi: 10.1038/s41598-018-35816-3.

6.

Relationship between low levels of circulating TRAIL and atheromatosis progression in patients with chronic kidney disease.

Arcidiacono MV, Rimondi E, Maietti E, Melloni E, Tisato V, Gallo S, Valdivielso JM, Fernández E, Betriu À, Voltan R, Zauli G, Volpato S, Secchiero P.

PLoS One. 2018 Sep 11;13(9):e0203716. doi: 10.1371/journal.pone.0203716. eCollection 2018.

7.

TRAIL and Ceruloplasmin Inverse Correlation as a Representative Crosstalk between Inflammation and Oxidative Stress.

Tisato V, Gallo S, Melloni E, Celeghini C, Passaro A, Zauli G, Secchiero P, Bergamini C, Trentini A, Bonaccorsi G, Valacchi G, Zuliani G, Cervellati C.

Mediators Inflamm. 2018 Jul 26;2018:9629537. doi: 10.1155/2018/9629537. eCollection 2018.

8.

Effects of Hypoxia and Bed Rest on Markers of Cardiometabolic Risk: Compensatory Changes in Circulating TRAIL and Glutathione Redox Capacity.

Biolo G, Di Girolamo FG, McDonnell A, Fiotti N, Mearelli F, Situlin R, Gonelli A, Dapas B, Giordano M, Lainscak M, Grassi G, Zauli G, Secchiero P, Mekjavic I.

Front Physiol. 2018 Jul 30;9:1000. doi: 10.3389/fphys.2018.01000. eCollection 2018.

9.

Cardiovascular disease-related miRNAs expression: potential role as biomarkers and effects of training exercise.

Ultimo S, Zauli G, Martelli AM, Vitale M, McCubrey JA, Capitani S, Neri LM.

Oncotarget. 2018 Mar 30;9(24):17238-17254. doi: 10.18632/oncotarget.24428. eCollection 2018 Mar 30. Review.

10.

Influence of physical exercise on microRNAs in skeletal muscle regeneration, aging and diseases.

Ultimo S, Zauli G, Martelli AM, Vitale M, McCubrey JA, Capitani S, Neri LM.

Oncotarget. 2018 Mar 30;9(24):17220-17237. doi: 10.18632/oncotarget.24991. eCollection 2018 Mar 30. Review.

11.

Physical training interventions for children and teenagers affected by acute lymphoblastic leukemia and related treatment impairments.

Simioni C, Zauli G, Martelli AM, Vitale M, Ultimo S, Milani D, Neri LM.

Oncotarget. 2018 Mar 30;9(24):17199-17209. doi: 10.18632/oncotarget.24762. eCollection 2018 Mar 30. Review.

12.

Oxidative stress: role of physical exercise and antioxidant nutraceuticals in adulthood and aging.

Simioni C, Zauli G, Martelli AM, Vitale M, Sacchetti G, Gonelli A, Neri LM.

Oncotarget. 2018 Mar 30;9(24):17181-17198. doi: 10.18632/oncotarget.24729. eCollection 2018 Mar 30. Review.

13.

Targeting the phosphatidylinositol 3-kinase/Akt/mechanistic target of rapamycin signaling pathway in B-lineage acute lymphoblastic leukemia: An update.

Simioni C, Martelli AM, Zauli G, Vitale M, McCubrey JA, Capitani S, Neri LM.

J Cell Physiol. 2018 Oct;233(10):6440-6454. doi: 10.1002/jcp.26539. Epub 2018 Apr 18. Review.

PMID:
29667769
14.

Impact of physical exercise in cancer survivors during and after antineoplastic treatments.

Ferioli M, Zauli G, Martelli AM, Vitale M, McCubrey JA, Ultimo S, Capitani S, Neri LM.

Oncotarget. 2018 Feb 8;9(17):14005-14034. doi: 10.18632/oncotarget.24456. eCollection 2018 Mar 2. Review.

15.

Gene-gene interactions among coding genes of iron-homeostasis proteins and APOE-alleles in cognitive impairment diseases.

Tisato V, Zuliani G, Vigliano M, Longo G, Franchini E, Secchiero P, Zauli G, Paraboschi EM, Vikram Singh A, Serino ML, Ortolani B, Zurlo A, Bosi C, Greco A, Seripa D, Asselta R, Gemmati D.

PLoS One. 2018 Mar 8;13(3):e0193867. doi: 10.1371/journal.pone.0193867. eCollection 2018.

16.

TRAIL reduces impaired glucose tolerance and NAFLD in the high-fat diet fed mouse.

Bernardi S, Toffoli B, Tisato V, Bossi F, Biffi S, Lorenzon A, Zauli G, Secchiero P, Fabris B.

Clin Sci (Lond). 2018 Jan 5;132(1):69-83. doi: 10.1042/CS20171221. Print 2018 Jan 16.

PMID:
29167318
17.

Roles and clinical implications of microRNAs in acute lymphoblastic leukemia.

Ultimo S, Martelli AM, Zauli G, Vitale M, Calin GA, Neri LM.

J Cell Physiol. 2018 Aug;233(8):5642-5654. doi: 10.1002/jcp.26290. Epub 2018 Feb 28. Review.

PMID:
29154447
18.

Low Circulating TRAIL Levels Are Associated with Increase of Resistin and Lipocalin-2/ngal Adipokines in Postmenopausal Women.

Tisato V, Secchiero P, Bonaccorsi G, Bergamini C, Greco P, Zauli G, Cervellati C.

Mediators Inflamm. 2017;2017:5356020. doi: 10.1155/2017/5356020. Epub 2017 Sep 5.

19.

The γ-secretase inhibitors enhance the anti-leukemic activity of ibrutinib in B-CLL cells.

Secchiero P, Voltan R, Rimondi E, Melloni E, Athanasakis E, Tisato V, Gallo S, Rigolin GM, Zauli G.

Oncotarget. 2017 Jul 22;8(35):59235-59245. doi: 10.18632/oncotarget.19494. eCollection 2017 Aug 29.

20.

Anti-leukemic activity of microRNA-26a in a chronic lymphocytic leukemia mouse model.

D'Abundo L, Callegari E, Bresin A, Chillemi A, Elamin BK, Guerriero P, Huang X, Saccenti E, Hussein EMAA, Casciano F, Secchiero P, Zauli G, Calin GA, Russo G, Lee LJ, Croce CM, Marcucci G, Sabbioni S, Malavasi F, Negrini M.

Oncogene. 2017 Nov 23;36(47):6617-6626. doi: 10.1038/onc.2017.269. Epub 2017 Aug 7.

21.

MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer.

Tisato V, Voltan R, Gonelli A, Secchiero P, Zauli G.

J Hematol Oncol. 2017 Jul 3;10(1):133. doi: 10.1186/s13045-017-0500-5. Review.

22.

Association between thyroid hormones and TRAIL.

Bernardi S, Bossi F, Toffoli B, Giudici F, Bramante A, Furlanis G, Stenner E, Secchiero P, Zauli G, Carretta R, Fabris B.

Clin Biochem. 2017 Nov;50(16-17):972-976. doi: 10.1016/j.clinbiochem.2017.05.011. Epub 2017 May 25.

23.

Inflammation and Cardiovascular Cross Talk in Ischemic Vascular Diseases.

Zauli G, Tisato V, Raffetto JD, Vaccarezza M.

Mediators Inflamm. 2017;2017:3161968. doi: 10.1155/2017/3161968. Epub 2017 Mar 26. No abstract available.

24.

PI3K isoform inhibition associated with anti Bcr-Abl drugs shows in vitro increased anti-leukemic activity in Philadelphia chromosome-positive B-acute lymphoblastic leukemia cell lines.

Ultimo S, Simioni C, Martelli AM, Zauli G, Evangelisti C, Celeghini C, McCubrey JA, Marisi G, Ulivi P, Capitani S, Neri LM.

Oncotarget. 2017 Apr 4;8(14):23213-23227. doi: 10.18632/oncotarget.15542.

25.

Synergistic effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway or NUP214-ABL1 fusion protein in human Acute Lymphoblastic Leukemia.

Simioni C, Ultimo S, Martelli AM, Zauli G, Milani D, McCubrey JA, Capitani S, Neri LM.

Oncotarget. 2016 Nov 29;7(48):79842-79853. doi: 10.18632/oncotarget.13035.

26.

Circulating levels of TNF-related apoptosis inducing-ligand are decreased in patients with large adult-type granulosa cell tumors-implications for therapeutic potential.

Färkkilä A, Zauli G, Haltia UM, Pihlajoki M, Unkila-Kallio L, Secchiero P, Heikinheimo M.

Tumour Biol. 2016 Sep;37(9):11909-11916. Epub 2016 Apr 11.

PMID:
27067438
27.

Multimodal near-infrared-emitting PluS Silica nanoparticles with fluorescent, photoacoustic, and photothermal capabilities.

Biffi S, Petrizza L, Garrovo C, Rampazzo E, Andolfi L, Giustetto P, Nikolov I, Kurdi G, Danailov MB, Zauli G, Secchiero P, Prodi L.

Int J Nanomedicine. 2016 Sep 22;11:4865-4874. eCollection 2016.

28.

Redox signaling and oxidative stress: Cross talk with TNF-related apoptosis inducing ligand activity.

Voltan R, Secchiero P, Casciano F, Milani D, Zauli G, Tisato V.

Int J Biochem Cell Biol. 2016 Dec;81(Pt B):364-374. doi: 10.1016/j.biocel.2016.09.019. Epub 2016 Sep 26. Review.

29.

Ibrutinib synergizes with MDM-2 inhibitors in promoting cytotoxicity in B chronic lymphocytic leukemia.

Voltan R, Rimondi E, Melloni E, Rigolin GM, Casciano F, Arcidiacono MV, Celeghini C, Cuneo A, Zauli G, Secchiero P.

Oncotarget. 2016 Oct 25;7(43):70623-70638. doi: 10.18632/oncotarget.12139.

30.

Healthy CD4+ T lymphocytes are not affected by targeted therapies against the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia.

Alameen AA, Simioni C, Martelli AM, Zauli G, Ultimo S, McCubrey JA, Gonelli A, Marisi G, Ulivi P, Capitani S, Neri LM.

Oncotarget. 2016 Aug 23;7(34):55690-55703. doi: 10.18632/oncotarget.10984.

31.

Serum Soluble Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Levels in Older Subjects with Dementia and Mild Cognitive Impairment.

Tisato V, Rimondi E, Brombo G, Volpato S, Zurlo A, Zauli G, Secchiero P, Zuliani G.

Dement Geriatr Cogn Disord. 2016;41(5-6):273-80. doi: 10.1159/000446275. Epub 2016 Jun 16.

32.

Metformin combined with sodium dichloroacetate promotes B leukemic cell death by suppressing anti-apoptotic protein Mcl-1.

Voltan R, Rimondi E, Melloni E, Gilli P, Bertolasi V, Casciano F, Rigolin GM, Zauli G, Secchiero P.

Oncotarget. 2016 Apr 5;7(14):18965-77. doi: 10.18632/oncotarget.7879.

33.

Clinical perspectives of TRAIL: insights into central nervous system disorders.

Tisato V, Gonelli A, Voltan R, Secchiero P, Zauli G.

Cell Mol Life Sci. 2016 May;73(10):2017-27. doi: 10.1007/s00018-016-2164-7. Epub 2016 Feb 24. Review.

34.

Design, Synthesis, and Biological Characterization of Novel Mitochondria Targeted Dichloroacetate-Loaded Compounds with Antileukemic Activity.

Trapella C, Voltan R, Melloni E, Tisato V, Celeghini C, Bianco S, Fantinati A, Salvadori S, Guerrini R, Secchiero P, Zauli G.

J Med Chem. 2016 Jan 14;59(1):147-56. doi: 10.1021/acs.jmedchem.5b01165. Epub 2015 Dec 23.

PMID:
26653539
35.

Kinetic Profiles of Inflammatory Mediators in the Conjunctival Sac Fluid of Patients upon Photorefractive Keratectomy.

Tisato V, Perri P, Rimondi E, Melloni E, Lamberti G, Milani D, Secchiero P, Zauli G.

Mediators Inflamm. 2015;2015:942948. doi: 10.1155/2015/942948. Epub 2015 Oct 7.

36.

Two‑gene mutation in a single patient: Biochemical and functional analysis for a correct interpretation of exome results.

Bianco AM, Faletra F, Vozzi D, Girardelli M, Knowles A, Tommasini A, Zauli G, Marcuzzi A.

Mol Med Rep. 2015 Oct;12(4):6128-32. doi: 10.3892/mmr.2015.4215. Epub 2015 Aug 11.

PMID:
26300074
37.

Applications of nanoparticles in cancer medicine and beyond: optical and multimodal in vivo imaging, tissue targeting and drug delivery.

Biffi S, Voltan R, Rampazzo E, Prodi L, Zauli G, Secchiero P.

Expert Opin Drug Deliv. 2015;12(12):1837-49. doi: 10.1517/17425247.2015.1071791. Epub 2015 Aug 9. Review.

PMID:
26289673
38.

The novel dual PI3K/mTOR inhibitor NVP-BGT226 displays cytotoxic activity in both normoxic and hypoxic hepatocarcinoma cells.

Simioni C, Cani A, Martelli AM, Zauli G, Alameen AA, Ultimo S, Tabellini G, McCubrey JA, Capitani S, Neri LM.

Oncotarget. 2015 Jul 10;6(19):17147-60.

39.

The combination of N-acetyl cysteine, alpha-lipoic acid, and bromelain shows high anti-inflammatory properties in novel in vivo and in vitro models of endometriosis.

Agostinis C, Zorzet S, De Leo R, Zauli G, De Seta F, Bulla R.

Mediators Inflamm. 2015;2015:918089. doi: 10.1155/2015/918089. Epub 2015 Apr 16.

40.

Serum TRAIL levels increase shortly after insulin therapy and metabolic stabilization in children with type 1 diabetes mellitus.

Tornese G, Tisato V, Monasta L, Vecchi Brumatti L, Zauli G, Secchiero P.

Acta Diabetol. 2015 Oct;52(5):1003-6. doi: 10.1007/s00592-015-0731-2. Epub 2015 Apr 12. No abstract available.

41.

TNF-related apoptosis inducing ligand in ocular cancers and ocular diabetic complications.

Perri P, Zauli G, Gonelli A, Milani D, Celeghini C, Lamberti G, Secchiero P.

Biomed Res Int. 2015;2015:424019. doi: 10.1155/2015/424019. Epub 2015 Mar 5. Review.

42.

Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia.

Cani A, Simioni C, Martelli AM, Zauli G, Tabellini G, Ultimo S, McCubrey JA, Capitani S, Neri LM.

Oncotarget. 2015 Mar 30;6(9):6597-610.

43.

TRAIL modulates the immune system and protects against the development of diabetes.

Bossi F, Bernardi S, Zauli G, Secchiero P, Fabris B.

J Immunol Res. 2015;2015:680749. doi: 10.1155/2015/680749. Epub 2015 Feb 18. Review.

44.

The p53 transcriptional pathway is preserved in ATMmutated and NOTCH1mutated chronic lymphocytic leukemias.

Athanasakis E, Melloni E, Rigolin GM, Agnoletto C, Voltan R, Vozzi D, Piscianz E, Segat L, Dal Monego S, Cuneo A, Secchiero P, Zauli G.

Oncotarget. 2014 Dec 30;5(24):12635-45.

45.

The anti-leukemic activity of sodium dichloroacetate in p53mutated/null cells is mediated by a p53-independent ILF3/p21 pathway.

Agnoletto C, Brunelli L, Melloni E, Pastorelli R, Casciano F, Rimondi E, Rigolin GM, Cuneo A, Secchiero P, Zauli G.

Oncotarget. 2015 Feb 10;6(4):2385-96.

46.

Intranasal administration of recombinant TRAIL down-regulates CXCL-1/KC in an ovalbumin-induced airway inflammation murine model.

Tisato V, Garrovo C, Biffi S, Petrera F, Voltan R, Casciano F, Meroni G, Agnoletto C, Zauli G, Secchiero P.

PLoS One. 2014 Dec 15;9(12):e115387. doi: 10.1371/journal.pone.0115387. eCollection 2014.

47.

Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent Akt reactivation.

Simioni C, Cani A, Martelli AM, Zauli G, Tabellini G, McCubrey J, Capitani S, Neri LM.

Oncotarget. 2014 Oct 30;5(20):10034-47.

48.

Osteoprotegerin increases in metabolic syndrome and promotes adipose tissue proinflammatory changes.

Bernardi S, Fabris B, Thomas M, Toffoli B, Tikellis C, Candido R, Catena C, Mulatero P, Barbone F, Radillo O, Zauli G, Secchiero P.

Mol Cell Endocrinol. 2014 Aug 25;394(1-2):13-20. doi: 10.1016/j.mce.2014.06.004. Epub 2014 Jul 3.

PMID:
24998520
49.

Association of serum tumor necrosis factor-related apoptosis inducing ligand with body fat distribution as assessed by dual X-rays absorptiometry.

Cervellati C, Secchiero P, Bonaccorsi G, Celeghini C, Zauli G.

Mediators Inflamm. 2014;2014:306848. doi: 10.1155/2014/306848. Epub 2014 May 21.

50.

Sodium dichloroacetate exhibits anti-leukemic activity in B-chronic lymphocytic leukemia (B-CLL) and synergizes with the p53 activator Nutlin-3.

Agnoletto C, Melloni E, Casciano F, Rigolin GM, Rimondi E, Celeghini C, Brunelli L, Cuneo A, Secchiero P, Zauli G.

Oncotarget. 2014 Jun 30;5(12):4347-60.

Supplemental Content

Support Center